Bristol-myers Squibb Compnay

Rutgers, the State University of New Jersey

Lexicon Pharmaceuticals, Inc.

Abbott Laboratories Corporation

The State University of New York

University of Pittsburgh

Astrazeneca Ab

David John Augeri

Lawrence G Hamann

Wang Shen

Kenneth Gordon Carson

Saul H Rosenberg

Theodore C Jessop

Jeffrey A Robl

John A Gilleran

Jeffrey Thomas Bagdanoff

Michael D Wendt

Hong Ding

Stephen W Fesik

David R Magnin

Daniel A Dickman

Sheela A Thomas

Stewart N Loh

Adam R Blanden

Darren R Carpizo

Spencer David Kimball

Anthony F Bencivenga

Xin Yu

William J McClellan

Tammy C Wang

Stephen J O'Connor

Marianne Carlsen

Philip J Hajduk

Stephen A Fakhoury

James E Tarver

Said M Sebti

Thorsten K Oost

Ramesh N Patel

Xilu Wang

Aaron R Kunzer

Milan Bruncko

Kenneth Jay Barr

Gerard M Sullivan

Andrew D Hamilton

David A Betebenner

Jollie D Godfrey, Jr

James J Li

Ronald L Hanson

Yingzhi Bi

Andrew M Petros

Jurgen Dinges

Jurong Yu

Qinghong Fu

David B Brzozowski

Sergei Kolotuchin

Jason J Zhu

Jianji Wang

Truc Chi Vu

Lakmal Boteju

David G Nettesheim

Rita Fox

John A Mazzullo

Kwok Wong

Steven A Baumeister

Andrew Stewart Tasker

Steven Elmore

Le Wang

Richard B Sulsky

James Clifford Sutton

Mark E Salvati

Chongqing Sun

Douglas M Kalvin

Alexander Heim-Riether

Rolf E Swenson

Kenneth J Henry

Jerry Andrew Taylor

Chong-qing Sun

Indrani W Gunawardana

James T Wasicak

Shengkan Jin

David A Janowick

Ligaya Simpkins

Lissa T J Nelson

Alexandra Holubec

Bin Cao

David S Garvey

Gang Liu

Bryan K Sorensen

Todd Warren Rockway

Anthony K Fung

Steven K Davidsen

William R Baker

Yan Guo

Michael Voronkov

David M Stout

Mark C Manfredi

David L Arendsen

S David Kimball

Richard A Craig

Herman H Stein

Michael R Michaelides

Hatem E Sabaawy

Simon David Peter Baugh

Jason Patrick Healy

Rajnandan N Prasad

Michael Mertzman

The disclosure provides in one aspect a method of treating, ameliorating, and/or preventing toxicity caused by a ribosome inactivating protein (RIP) in a subject. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one compound of the disclosure.

Compositions and methods for inhibiting ribosome inactivating proteins

The invention provides compounds of formula (16) and (17); and salts thereof, as well as compositions comprising such compounds and salts, complexes comprising such compounds and salts, and methods for treating cancer, inhibiting BMI1 expression, or treating Huntington's disease using such compounds, salts, and complexes. The compounds, salts, and complexes have potency, permeability, and oral bioavailability that make them particularly useful, for example, for the treatment of glioblastoma.

Pharmaceutical compounds and therapeutic methods

The invention provides a compound of formula I: or a salt thereof, wherein R-Rand p have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as anti-cancer agents.

Therapeutic compounds

The invention provides compounds of formula (I): and salts thereof wherein ring A, R, HET, X, n, and Rhave any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts. 

Hydrazone derivatives for the treatment of cancer

The invention provides complexes of Zn2+ of formulae (la) and (IIa) that are useful for treating cancer, as well as compositions and kits comprising such complexes. 

Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer

The invention provides organic complexes of Znthat are useful for treating cancer, as well as compositions and kits comprising such complexes, and intermediate monomer compounds that are useful for the preparation of such complexes.

(Thio, oxo and seleno) semicarbazone complexes with zinc and their use for treating cancer

The invention provides compounds of formula I and II and salts thereof, wherein R, R, Y, R, and Rhave any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts. 

(Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancer

2-hydroxy-benzoic anilide compounds and derivatives, compositions thereof, and methods for treating metabolic diseases and cancer through uncoupling mitochondria.

Mitochondrial uncouplers for treatment of metabolic diseases and cancer

The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, Non-Alcholic Fatty Liver Disease (NAFLD), Non-Alcholic Steathohepatitis (NASH), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.

The invention provides organic complexes of Znof formula (I) that are useful for treating cancer, as well as compositions and kits comprising such complexes, and intermediate monomer compounds that are useful for the preparation of such complexes. 

(Thio, oxo, and seleno) semicarbazone complexes with zinc and their use for treating cancer

Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders. Particular compounds are of the formula: 

MST1 kinase inhibitors and methods of their use

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.

Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method

Methods of treating and managing ulcerative colitis, using imidazole-based compounds that inhibit S1P lyase, are disclosed.

Methods of treating ulcerative colitis

Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.

Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof

Aryl pyridines, compositions comprising them, and methods of their use for the treatment, prevention and management of a variety of diseases and disorders are disclosed.

Aryl pyridines and methods of their use

Growing community of inventors

Princeton, NJ, United States of America

David John Augeri